Aileron Therapeutics (ALRN) to Offer Common Stock

Aileron Therapeutics (NASDAQ: ALRN) announced today that it has commenced an underwritten public offering of shares of its common stock. Aileron also intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the public offering. All of the shares are being offered by Aileron.

Aileron expects to use the net proceeds from the offering, together with its existing cash, cash equivalents and short-term investments, to fund clinical development of ALRN-6924 as a chemoprotective agent and for working capital and other general corporate purposes.

William Blair & Company, L.L.C. is acting as sole book-running manager for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

You May Also Be Interested In

• Alto Neuroscience prices $100M stock offering to fund depression trial
• Elong Power closes $6.6M public offering on Nasdaq
• Research Alliance Corporation IV prices $75M IPO on Nasdaq